Click Targets ‘Best-In-Class Digital Therapy For Chronic Weight Management’ With Better Therapeutics Acquisition

Firm Says Its Digital Therapeutic Will Combine With GLP-1s For Optimal Obesity Treatment

Click will fold Better Therapeutics’ FDA-cleared AspyreRx prescription digital therapeutic into R&D for its own CT-181, which promises to optimize obesity treatment in combination with drugs such as GLP-1s and provide "valuable real-world data insights for providers and payers." Better Therapeutics shuttered its operations in March, signaling continued challenges for digital medicine innovators.

• Source: Shutterstock

Click Therapeutics, Inc.’s acquisition of Better Therapeutics, Inc.’s AspyreRx – the first FDA-authorized prescription digital therapeutic (PDT) for type-2 diabetes – among other assets, reflects the company’s growing focus on obesity and cardiometabolic disease amid the GLP-1 agonist boom.

“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” says...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

More from Business